ABSTRACT: Water-soluble vitamin B3, niacin, and its related compounds were suggested to be applicable for medical use. In this article, we examined the anti-leukemic effects of two distinct histone deacetylase (HDAC1 and Sir2) inhibitors, sodium phenyl butyrate (PB) and vitamin B3, respectively, on human promyelocytic leukemia cells HL-60, using HDACIs alone and in combination with all trans retinoic acid (RA). We demonstrated that the HDACI combinations exert different effects on cell cycle arrest and differentiation as determined by nitro blue reduction and the expression of the early myeloid differentiation marker CD11b. The most beneficial effects were found by use of 6-h pretreatment with PB and vitamin B3 before the exposition to RA alone or in combination with vitamin B3, showing significant acceleration and a high level of granulocytic differentiation. The effects were associated with a rapid histone H4 acetylation and later histone H3 modifications. Our results suggest that the use of two HDACI altogether before the induction of differentiation and acting via chromatin remodeling may be promising for the treatment of acute promyelocytic leukemia.
INTRODUCTION
Histone deacetylase inhibitors (HDACI) comprise a new class of potential anticancer agents for the treatment of solid and hematological malignancies. They have generated significant interest due to their ability to cause growth arrest, terminal differentiation, and/or apoptosis in cancer cells. HDAC inhibition causes acetylated nuclear histones to accumulate in both tumor and normal tissues. The effects of HDACI on gene expression are highly selective, leading to transcriptional activation/deactivation of certain genes.
1-3 HDAC inhibition also results in the activation of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) and inhibition of transcription factors, such as p53, GATA-1, and estrogen receptor-␣. 4, 5 The functional significance of protein acetylation and the precise mechanisms, whereby HDACI induce tumor cell growth arrest, differentiation, and/or apoptosis, are currently the focus of intensive research. Several HDACI, e.g., sodium phenyl butyrate (PB), valproic acid, and novel compounds, such as depsipeptide, have shown impressive antitumor activity in vivo with remarkably little toxicity in preclinical studies and have currently entered the clinical arena. 6 Acute promyelocytic leukemia (APL) is characterized by the expansion of malignant myeloid cells blocked at the promyelocytic stage of hematopoietic development and is invariably associated with reciprocal chromosomal translocations involving the retinoic acid receptor-␣ (RAR␣) gene. 7 New understanding in APL pathogenesis is obtained through novel therapeutic strategies with, for instance, HDACI and inorganic arsenicals, such as As 2 O 3. These are currently being tested in murine leukemia models as well as in humans with APL. 8 Agents, such as all-trans retinoic acid (RA), sodium PB, and As 2 O 3 , which induce differentiation or apoptosis in APL, have been shown to successfully achieve remission. Recently, it was shown that several niacin-related compounds, such as vitamin B3 (vitB3), isonicotinamide and others, belonging to Sir2 family of HDAC, had a differentiation activity in leukemia cells. 9 In our study, we used the histone deacetylase HDAC1 and Sir2 inhibitors, sodium PB and vitB3, respectively, alone and in combination with the differentiation agent, all-trans RA, in human promyelocytic leukemia cell line HL-60. We found the most promising combination for differentiation therapy defined by 6-h pretreatment with PB and vitB3 before exposition to RA alone or with vitB3. Such treatment significantly accelerated and increased cell differentiation (up to 95%) during the 48-h treatment.
MATERIALS AND METHODS

Cell Culture
The human promyelocytic leukemia cell line HL-60 was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 g/mL streptomycin (Gibco, Grand Island, NY). Cells were grown at 37
• C in a humidified 5% CO 2 atmosphere and used for assays during the exponential phase of growth. Sodium PB (Calbiochem, San Diego, CA) was dissolved in water at a concentration of 1 mM and stored at -20
• C. VitB3 nicotinamide (Sigma, St. Louis, MO) was dissolved in RPMI medium at a concentration 1 mM and stored at +4
• C. All-trans-RA (Sigma) was dissolved in ethanol at a concentration 500 M and stored at -20
• C. Cells were harvested for further analysis either before or after various time points of treatment with 3 mM PB, 5 mM vitB3, and 1 M RA or their combinations.
Assessment of Cell Viability and Differentiation
Viable cells were detected by exclusion of 0.2% trypan blue and counted in a hemocytometer. Granulocytic differentiation of HL-60 cells was determined by NBT reduction.
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Cell Cycle Analysis
Cell cycle progression was monitored by quantitating cellular DNA content after staining with propidium iodide (PI). Untreated, HDACI-and RAtreated cells were collected by centrifugation, suspended in PBS, and fixed in ice-cold 70% ethanol (ratio 1:10) for 24 h at -20
• C. After centrifugation at 500 g for 5 min, cells were suspended in PBS containing PI (50 g/mL) and RNAse (0.2 mg/mL) and incubated at room temperature for 30 min. The tubes were then maintained at 4
• C in the dark until analysis using a flow cytometer (Becton-Dickinson FACSCalibur, San Jose, CA). The percentage of cells in G0/G1, S, and G2/M phases was evaluated with CellQuest software (Becton-Dickinson FACSCalibur).
Cell Surface Antigen Analysis
Control and drug-treated HL-60 cells (5 × 10 5 cells/sample) were collected, washed twice with PBS, and suspended in 50 L PBS, pH 7.4. Then 5 L of monoclonal mouse anti-human CD11b, C3bi receptor/RPE (DakoCytomation, Glostrup, Denmark) antibody was added to the sample and gently suspended and incubated in the dark at 4
• C for 30 min. Cells were washed with PBS containing 2% bovine serum albumin, fixed in 4% paraformaldehyde for 15-30 min on ice, and the pellet was resuspended in PBS. Eight thousands events were analyzed for each sample by immunofluorescence using flow cytometry. Proliferating cells with and without anti-CD11b antibodies were used as a control.
Isolation of Cell Nuclei
Cells (5 × 10 6 to 10 7 ) were harvested by centrifugation at 500 g for 6 min, washed twice in ice cold PBS, and suspended in Nuclei EZ lysis buffer (Sigma). Nuclei were isolated according to the manufacturer's protocol (Sigma). Nuclei were washed in the same cold Nuclei EZ buffer, vortexed briefly and set on ice for 5 min, then pelleted at 500 g for 5 min, completely resuspended in nuclei EZ storage buffer (Sigma) and frozen at -70
• C.
Isolation and Fractionation of Histones
Histones were extracted, as described previously by Treigyte and Gineitis.
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Isolated nuclei were suspended in 5 vol of 0.4 N H 2 SO 4 by stirring and incubated overnight at 0 • C. The supernatant was collected by centrifugation at 15,000 g for 10 min at +2
• C and the sediment was extracted once more. After centrifugation, both extracts were combined and histones precipitated by adding 5 vol of ethanol at −20
• C overnight. Precipitated histones were collected by centrifugation, washed several times with ethanol, and kept in −20
• C until analysis. Histone electrophoresis was carried out essentially as described by Hurley. 12 Histones (5 g) were dissolved in a buffer containing 0.9 M acetic acid, 10% glycerol, 6.25 M urea, and 5% ␤-mercaptoethanol, and run on a 15% polyacrylamide gel containing 6 M urea and 0.9 M acetic acid for 3 h at 12 mA and 500 V by using 0.9 M acetic acid as buffer. Histones were transferred to Immobilon TM PVDF transfer membrane (Millipore, Bedford, MA) and analyzed with antibodies against hyperacetylated histone H4 (Penta), phosphorylated histone H3 (Ser10) (Upstate, Lake Placid, NY) and Phospho (Ser10) Acetyl (Lys9) histone H3 (Abcam plc, Cambridge, UK). Thereafter, the membranes were subsequently washed with PBS-Tween-20 and incubated with horseradish peroxidase-conjugated secondary antibody (DAKO, A/S, Glostrup, Denmark) for 1 h at room temperature. Then, the filters were washed as described earlier and immunoreactive bands detected by enhanced chemiluminescence using ECL TM Western blotting detection reagents (Amersham Pharmacia, Uppsala, Sweden), according to the instructions of the manufacturer.
RESULTS
Effects of HDACIs and RA on HL-60 Cell Growth and Granulocytic Differentiation
In order to examine the effects of HDACIs and the differentiation inducer RA on HL-60 cell growth and differentiation, the cells were treated with PB, vitB3, or RA alone or in combination for 1-5 days (FIG. 1 A, D) . As seen in FIGURE 1 A, all used agents and their combinations, inhibited cell growth. FIGURE 1 B presents the cell differentiation level caused by PB, vitB3, or RA alone, and their combinations. RA caused differentiation up to 90% after 5 days of treatment. PB induced it up to 30%, while vitB3 did not induce granulocytic differentiation.
To examine the differentiating effects of HDACIs and RA combinations, cells were first pretreated with PB alone or together with vitB3 for 6 h, and then treated with RA alone or together with vitB3 (FIG. 1 C, D) . The combined HDACI pretreatment before the exposition to RA alone or with vitB3 resulted in the elevation of differentiation up to 65% (at 24 h) and 95% (at 48 h). These results demonstrate that the combined pretreatment with two different classes of HDACI, PB and vitB3, before the induction of differentiation by RA causes the acceleration and augmentation of HL-60 cell differentiation to granulocytes.
Influence of Combinatorial Treatment of HDACIs and RA on Cell Cycle
Progression and the Expression of the Early Myeloid Differentiation Marker CD11b in HL-60 Cells that treatment with PB, vitB3, and RA alone or in combination caused a decrease in the S and increase in the G0/G1 phases. When cells were pretreated with a combination of PB and vitB3 followed by treatment with RA alone or together with vitB3, a considerable increase up to 65% at 24 h (data not shown) with further increase up to 79% at 48 h was detected in the G0/G1 phase (FIG. 2) .
We further examined the influence of HDACIs and RA on the early myeloid differentiation marker CD11b expression in HL-60 cells (FIG. 3) . A 6-h pretreatment with PB and vitB3 before a 24-h treatment with RA alone or together with vitB3 caused about 85% cells expressing CD11b in both cases. After 48 h of such treatments, the CD11b expression diminished up to 74% and 56%, respectively. In contrast to other treatments presented in FIGURE 3, HDACIs and RA combinations increased to a considerable extent the cell number entering to differentiation program during the first 24 h of treatment.
Thus, these results demonstrate that combinatorial treatment of two HDACI and RA caused cell cycle arrest in the G0/G1 phase and marked increase in the expression of early myeloid differentiation marker CD11b in HL-60 cells. This combination could be most promising for the differentiation therapy of leukemia. 
Histone H3 and H4 Modifications Caused by HDACIs and RA Treatments
The differentiation agent RA and two HDACIs, PB and vitB3, were used to study their influence on histone H4 hyperacetylation in HL-60 cells. As can be seen in FIGURE 4, in control-proliferating HL-60 cells histone H4 is present in Ac0 and Ac1 forms. After treatment with vitB3 and RA, histone H4 becomes acetylated and is present at Ac0, Ac1, Ac2, and Ac3 forms. Only PB caused histone H4 hyperacetylation, which occurred during first 3-6 h of treatment. When PB and vitB3 were used in combination (FIG. 5) , histone H4 mainly displayed the Ac4 form. During the first hours of such treatment, the phosphorylation (Ser10) and acetylation (Lys9) /phosphorylation (Ser10) of histone H3 was not detected or was detected only at a very low level (FIG. 5) .
Thus, the combined HDACIs and RA treatment caused acetylation of histone H4 (Ac2-4 forms) and low level of histone H3 modifications.
DISCUSSION
Although the standard approach to treating myeloid leukemia remains chemotherapy, recent advances in the understanding of the biology of these disorders have lead to the development of targeted treatment strategies. The organization of chromatin is crucial for the regulation of gene expression. Histones from control and treated HL-60 cells for indicated time points were resolved on 15% polyacrylamide-acetic acid-urea (AU) gels and examined by Western blot analysis by using antibodies against hyperacetylated histone H4 forms. The acetylation state of histones is indicated representing un-acetylated (Ac 0), mono-(Ac 1), di-(Ac 2), tri-(Ac 3), and tetra-(Ac 4) acetylated forms.
FIGURE 5.
Modifications of histone H4 and H3 in response to HDACIs and RA. HL-60 cells were treated with 5 mM vitB3 together with 3 mM PB (vitB3 + PB) for indicated time points or pretreated with 5 mM vitB3 and 3 mM PB for 6 h before 48 h treatment with 1 M RA alone (vitB3 + PB→ RA) or together with 5 mM vitB3 (vitB3 + PB→ RA + vitB3). Histones from control or treated HL-60 cells were resolved on 15% polyacrylamide-acetic acid-urea (AU) gels and examined by Western blot analysis using specific antibodies against Acetyl (Lys9) Phospho (Ser10) H3 and against Phospho (Ser10) H3. The acetylation state of histone H4 is indicated representing un-acetylated (Ac 0), mono-(Ac 1), di-(Ac 2), tri-(Ac 3), and tetra-(Ac 4) acetylated forms.
In particular, both the positioning and properties of nucleosomes influence promotor-specific transcription in response to extracellular or intracellular signals. 13 Several leukemogenic transcription factors repress expression of specific genes because of aberrant recruitment of HDACs. This repression of gene expression appears to be an important step in the action of these transcription factors, and aberrant recruitment of HDAC activity has been reported in cell lines derived from patients with APL. [14] [15] [16] Furthermore, resistance to the differentiating actions of all trans RA in patients with APL has been overcome by co-treatment with inhibitors of HDAC. 17 In our study, we investigated the in vitro antileukemic effects of inhibitors of two different classes (HDAC1 and Sir2) of HDAC, PB and vitB3, respectively, or in combination with RA on human promyelocytic leukemia HL-60 cell line. Both HDACIs, PB and vitB3, interfered with HL-60 cell proliferation and differentiation. Thus, PB and vitB3, as well as RA, inhibited the proliferation of promyelocytic leukemia HL-60 cells. The growth inhibition induced by HDACIs, PB and vitB3, and RA alone or in various their combinations was associated in particular with cell cycle arrest in the G0/G1 phase. Cell cycle regulation in the G1 phase has attracted a great deal of attention as a promising target for research on cancer treatment. Many of the important genes associated with G1 regulation have been shown to play a key role in proliferation, differentiation, and oncogenic transformation and programmed cell death. Currently, a variety of cytostatic agents that affect G1 progression or G1/S transition, are being evaluated in clinical trials. 5, 18, 19 Furthermore, we demonstrated that 6-h pretreatment with PB and vitB3 before exposition to RA alone or together with vitB3 significantly accelerated and increased cell differentiation (up to 95%) during 48 h of treatment; this is considered to be associated with the G1 block in cell cycle progression. Our results show that HL-60 cells became committed to differentiation already after the first 24 h of treatment, when 85% of cells expressed the early differentiation marker CD11b. After 48 h, the expression of CD11b reduced up to 56%, indicating that HL-60 cells become differentiated into granulocyte-like cells.
Posttranslational modifications of histones, such as acetylation, phosphorylation, and methylation, are common modes for chromatin remodeling. We observed rapid histone H4 acetylation and subsequent histone H3 phosphoacetylation in HL-60 cells after treatment with HDACI alone or in combination with RA. The increased level of histone H4 acetylation was associated with the initiation and maturation stages of HL-60 cell differentiation. In HL-60 and CCRF-CEM cells treated with HDACI trichostatin A, Chambers and co-workers 20 found by microarray analyses the functional link between histone acetylation and the expression profiles of approximately 12,000 genes. It comprised at least 9% of the genome.
The data about nucleosomes, containing phosphorylated and acetylated H3, point to the fact that both modifications may cooperate to facilitate transcription of certain genes. 21 Phosphorylated and/or acetylated H3 may promote gene activation-these modifications may serve as recognition sites for the recruitment of transcription factors or regulatory complexes. 22 Li and others 23 demonstrated that the treatment of NB4 cells with arsenic trioxide markedly increased histone H3 phosphorylation at serine 10, an event that is associated with acetylation of the lysine 14 residues. Furthermore, arsenic trioxide is highly effective for the treatment of APL, even in patients who are unresponsive to RA therapy. Our results show that histone H3 phosphoacetylation slightly increased after the combined treatment of HDACIs and RA, which could be associated with altered gene transcription during granulocytic differentiation. Taken together, the combination defined by us (i.e., 6-h pretreatment with two classes of HDACI, PB and vitB3, before the exposition to RA alone or in combination with vitB3) may be promising for differentiation therapy acting via chromatin remodeling.
